NOVYY IMMUNOMODULYaTOR REFNOT V LEChENII ONKOLOGIChESKIKh BOL'NYKh
- Авторлар: Kadagidze Z.G1, Slavina E.G1, Abramov M.E1, Vyshinskaya G.V1, Darenskaya A.D1
-
Мекемелер:
- Шығарылым: № 8 (2013)
- Беттер: 71-74
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/281252
- ID: 281252
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The new domestic immunomodulator Refnot is a combination of a recombinant tumor necrosis factor a and thymosin-α1. The article presents the results of studies on the application of Refnot as a monotherapy and in combination with chemotherapy in a number of malignant tumors (mainly in disseminated melanoma of the skin) in 55 patients who have exhausted the possibilities of a standard drug treatment. Efficacy of monotherapy with Refnot (stable disease) was 28 %. Disease control against the background of treatment with Refnot in combination with chemotherapy was achieved in 54,5% of cases. It has been shown that Refnot has a positive impact on anti-tumor immunity. Unlike other known immunomodulators this drug simultaneously positively influence the two cell populations -T-lymphocytes and NK-cells, which are major components of antitumor immunity.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Varfolomeev E., Goncharov T., Maecker H., et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors, Sci Signal 2012;5(216):ra22.
- Qidwai T., Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 2011;74(6):522-47.
- Vujanovic N.L. Role of TNF superfamily ligands in innate immunity. Immunol Res 2011;50(2-3):159-74.
- Vujanovic N.L. Role of TNF family ligands in antitumor activity of natural killer cells. Int Rev Immunol 2001;20(3-4):415-37.
- Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its super family: 25 years later, a golden journey. Blood 2012;119(3):651-65.
- Heerschap A., Fiedler W., Marreaud S, et al; EORTC New Drug Development Group. A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041). 2007 ASCO Annual Meeting. J Clin Oncol 2007;25(18S):14074.
Қосымша файлдар
